Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;78(3):297-301.
doi: 10.4046/trd.2015.78.3.297. Epub 2015 Jun 30.

Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy

Affiliations

Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy

Yeon-Hee Park et al. Tuberc Respir Dis (Seoul). 2015 Jul.

Abstract

Malignant mesothelioma is a rare malignant neoplasm that arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. Typically, pleural fluid cytology or closed pleural biopsy, surgical intervention (video thoracoscopic biopsy or open thoracotomy) is conducted to obtain pleural tissue specimens. However, endobronchial lesions are rarely seen and cases diagnosed from bronchoscopic biopsy are also rarely reported. We reported the case of a 77-year-old male who was diagnosed as malignant mesothelioma on bronchoscopic biopsy from obstructing masses of the endobronchial lesion.

Keywords: Biopsy; Bronchoscopy; Mesothelioma, Malignant.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Large amount of pleural effusion with passive collapse of right middle lobe and right lower lobe on chest radiography (A) and peribronchial soft tissue thickening in right middle lobe and right lower lobe on chest computed tomography (B, C).
Figure 2
Figure 2. Positron emission tomography computed tomography showed multiple high uptake lesions (A-C), and bronchoscopic biopsy was obtained from anterobasal segment of right lower lobe (D-F).
Figure 3
Figure 3. (A-D) Initial bronchoscopic biopsy findings of papillary clusters of epithelioid cells, and positive staining with anti-calretinin antibody, cytokeratin 5/6, and Wilms tumor 1 stain in most of the neoplastic cells. (E-H) Pleural biopsy findings of neoplastic cells positive for anti-calretinin antibody, and cytokeratin 5/6, and definitive Wilms tumor 1. (I-L) Follow-up bronchoscopic biopsy findings of neoplastic cells positive for anti-calretinin antibody, and negative for p63, Wilms tumor 1 stain.
Figure 4
Figure 4. After 4 cycles of chemotherapy, decreased pleural effusion on chest radiography (A) and decreased peribronchial soft tissue thickening and pleural nodules in right middle lobe and right lower lobe were observed (B, C).

References

    1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–588. - PubMed
    1. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–2090. - PMC - PubMed
    1. Kim HR, Ahn YS, Jung SH. Epidemiologic characteristics of malignant mesothelioma in Korea. J Korean Med Assoc. 2009;52:449–455.
    1. Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, et al. Malignant peritoneal mesothelioma. Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–218. - PubMed
    1. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma: an update on treatment. Cancer Treat Rev. 2012;38:605–612. - PubMed